Research programme: peptide therapeutics - AstraZeneca/EvoRx Technologies

Drug Profile

Research programme: peptide therapeutics - AstraZeneca/EvoRx Technologies

Latest Information Update: 22 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; EvoRx
  • Class Peptides
  • Mechanism of Action Protein-protein interaction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiration disorders

Most Recent Events

  • 09 Jul 2015 AstraZeneca and EvoRx Technologies collaborate to develop cell penetrating peptides for Respiratory disorders
  • 09 Jul 2015 Preclinical trials in Respiration disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top